PMID- 31841195
OWN - NLM
STAT- MEDLINE
DCOM- 20201015
LR  - 20210311
IS  - 2284-0729 (Electronic)
IS  - 1128-3602 (Linking)
VI  - 23
IP  - 23
DP  - 2019 Dec
TI  - LncRNA DLEU1/microRNA-300/RAB22A axis regulates migration and invasion of breast 
      cancer cells.
PG  - 10410-10421
LID - 19680 [pii]
LID - 10.26355/eurrev_201912_19680 [doi]
AB  - OBJECTIVE: To explore the possible role of deleted in lymphocytic leukemia 1 
      (DLEU1) in regulating the metastasis of breast cancer and its underlying 
      mechanism. PATIENTS AND METHODS: The expression levels of DLEU1 in 60 cases of 
      breast cancer tissues and adjacent normal tissues were detected by quantitative 
      Real Time-Polymerase Chain Reaction (qRT-PCR). Survival analysis and receiver 
      operating characteristic (ROC) curves were introduced to analyze the correlation 
      between DLEU1 expression and the clinical features of enrolled breast cancer 
      patients. After altering expressions of DLEU1, RAB22A or microRNA-300 by plasmid 
      transfection, the abilities of breast cancer cells to migrate and invade were 
      evaluated by transwell assay. Western blot was conducted to detect protein level 
      changes of epithelial-mesenchymal transition (EMT)-related genes regulated by 
      DLEU1, RAB22A or microRNA-300. Dual-luciferase reporter gene assay was performed 
      to detect the binding relation between microRNA-300 with DLEU1 and RAB22A. 
      RESULTS: DLEU1 expression remains higher in breast cancer tissues than in normal 
      adjacent tissues, and has a certain diagnostic value. The overall survival of 
      breast cancer patients was negatively correlated with DLEU1 expression. 
      Overexpression of DLEU1 or RAB22A, or microRNA-300 knockdown could enhance the 
      migratory and invasive capacities, as well as increase EMT ofBT549 cells. On the 
      contrary, knockdown of DLEU1 or RAB22A, or microRNA-300 overexpression in MCF-7 
      cells obtained the opposite trends of cellular behaviors. Dual-luciferase 
      reporter gene assay confirmed that DLEU1 and RAB22A could bind to microRNA-300. 
      Further verification showed that RAB22A expression was positively regulated by 
      DLEU1, but negatively regulated by microRNA-300. Finally, we found that DLEU1 
      overexpression could reverse the inhibitory effects of microRNA-300 on 
      proliferation, migration, and EMT of breast cancer cells. CONCLUSIONS: DLEU1 is 
      highly expressed in breast cancer, which promotes migration, invasion, and EMT of 
      breast cancer cells by targeting microRNA-300 to mediate RAB22A.
FAU - Wang, C
AU  - Wang C
AD  - Department of Breast Oncology, Cancer Hospital of China Medical University, 
      Shenyang, China. jiangzy968@163.com.
FAU - Xie, X-X
AU  - Xie XX
FAU - Li, W-J
AU  - Li WJ
FAU - Jiang, D-Q
AU  - Jiang DQ
LA  - eng
PT  - Journal Article
PL  - Italy
TA  - Eur Rev Med Pharmacol Sci
JT  - European review for medical and pharmacological sciences
JID - 9717360
RN  - 0 (DLEU1 lncRNA, human)
RN  - 0 (MIRN300 microRNA, human)
RN  - 0 (MicroRNAs)
RN  - 0 (RAB22A protein, human)
RN  - 0 (RNA, Long Noncoding)
RN  - 0 (Tumor Suppressor Proteins)
RN  - EC 3.6.5.2 (rab GTP-Binding Proteins)
SB  - IM
MH  - Breast/pathology/surgery
MH  - Breast Neoplasms/*genetics/mortality/pathology
MH  - Cell Movement/genetics
MH  - Cell Proliferation/genetics
MH  - Epithelial-Mesenchymal Transition/genetics
MH  - Female
MH  - Gene Expression Regulation, Neoplastic
MH  - Gene Knockdown Techniques
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - MCF-7 Cells
MH  - Mastectomy
MH  - MicroRNAs/genetics/*metabolism
MH  - Middle Aged
MH  - Neoplasm Invasiveness/genetics
MH  - Prognosis
MH  - RNA, Long Noncoding/genetics/*metabolism
MH  - Tumor Suppressor Proteins/genetics/*metabolism
MH  - rab GTP-Binding Proteins/*genetics
EDAT- 2019/12/17 06:00
MHDA- 2020/10/21 06:00
CRDT- 2019/12/17 06:00
PHST- 2019/12/17 06:00 [entrez]
PHST- 2019/12/17 06:00 [pubmed]
PHST- 2020/10/21 06:00 [medline]
AID - 19680 [pii]
AID - 10.26355/eurrev_201912_19680 [doi]
PST - ppublish
SO  - Eur Rev Med Pharmacol Sci. 2019 Dec;23(23):10410-10421. doi: 
      10.26355/eurrev_201912_19680.